Jim Kastenmayer
Algemeen Adviseur bij ARRIVENT BIOPHARMA, INC.
Vermogen: 114 778 $ op 30-04-2024
Profiel
Jim Kastenmayer is currently the Secretary & General Counsel at Arrivent BioPharma, Inc. He previously worked as the Legal Director & Senior Patent Director at AstraZeneca PLC from 2012 to 2019.
He also worked as the Secretary & General Counsel at Spyre Therapeutics, Inc. from 2021 to 2023 and at Viela Bio, Inc. from 2020 to 2021.
Additionally, he worked as an IP Counsel at Medimmune, Inc. Dr. Kastenmayer holds a doctorate degree from Michigan State University, an undergraduate degree from the University of Virginia, and a graduate degree from Georgetown University Law Center.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ARRIVENT BIOPHARMA, INC.
0.02% | 25-01-2024 | 7 386 ( 0.02% ) | 114 778 $ | 30-04-2024 |
Actieve functies van Jim Kastenmayer
| Bedrijven | Functie | Begin |
|---|---|---|
| ARRIVENT BIOPHARMA, INC. | Algemeen Adviseur | 01-09-2023 |
Eerdere bekende functies van Jim Kastenmayer
| Bedrijven | Functie | Einde |
|---|---|---|
| SPYRE THERAPEUTICS, INC. | Algemeen Directeur | 29-11-2022 |
| VIELA BIO, INC. | Algemeen Adviseur | 01-03-2021 |
| ASTRAZENECA PLC | Algemeen Adviseur | 01-12-2019 |
| Medimmune, Inc. | Corporate Officer/Principal | - |
Opleiding van Jim Kastenmayer
| Georgetown University Law Center | Graduate Degree |
| Michigan State University | Doctorate Degree |
| University of Virginia | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| SPYRE THERAPEUTICS, INC. | Health Technology |
| ARRIVENT BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Viela Bio, Inc.
 Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD. | Health Technology |
| Medimmune, Inc. | Health Technology |